ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.4300
-0.1600 (-0.86%)
As of 1:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close18.5900
Open18.5200
Bid18.3700 x 800
Ask18.4300 x 1000
Day's Range18.1400 - 18.8900
52 Week Range17.1700 - 35.7400
Volume164,793
Avg. Volume177,312
Market Cap1.071B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.6270
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China

    SHANGHAI, China, Sept. 12, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, will host a conference call and webcast to discuss its exclusive regional license and collaboration ...

  • Business Wire6 days ago

    Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China

    Novocure (NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. This agreement will enable Novocure to access the Chinese market and is intended to accelerate clinical trial enrollment.

  • Here's Why Zai Lab Limited Dropped Today
    Motley Fool12 days ago

    Here's Why Zai Lab Limited Dropped Today

    A secondary offering has investors hitting the sell button.

  • GlobeNewswire13 days ago

    Zai Lab Announces Pricing of Public Offering of American Depositary Shares

    SHANGHAI, China, Sept. 06, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced the pricing of its underwritten public offering of $150,000,000 of American Depositary ...

  • GlobeNewswire16 days ago

    Zai Lab Announces Proposed Public Offering of American Depositary Shares

    Zai Lab Limited (“Zai Lab” or the “Company”) (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”) representing ordinary shares of the Company. All ADSs will be offered by Zai Lab. In addition, Zai Lab expects to grant the underwriters a 30-day option to purchase up to $22,500,000 of additional ADSs.

  • GlobeNewswire19 days ago

    Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018

    SHANGHAI, China, Aug. 30, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced financial results for the six months ended June 30, 2018, and provided a corporate ...

  • Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher
    Zacks20 days ago

    Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher

    Zai Lab (ZLAB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • GlobeNewswire21 days ago

    Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced dosing of the first patient in a Phase III trial of ZL-2306 (niraparib) in patients with small-cell lung cancer (SCLC). The Phase III trial is a double-blind, placebo-controlled study randomizing 591 patients 2:1 for ZL-2306 (niraparib) vs. placebo as maintenance therapy with extensive-stage disease SCLC (ED-SCLC) who have responded to multiple cycles of first-line platinum-based chemotherapy. “Maintenance therapy for SCLC patients who have responded to first-line therapy is urgently needed to extend survival but no such treatment has yet been approved anywhere in the world,” said Dr. Samantha Du, Chief Executive Officer of Zai Lab.

  • Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
    Zacks22 days ago

    Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails

    Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.

  • GlobeNewswire25 days ago

    Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis

    SHANGHAI, China, Aug. 24, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced the decision to discontinue the development of ZL-3101 for the treatment of atopic ...

  • GlobeNewswire27 days ago

    Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC)

    SHANGHAI, China, Aug. 22, 2018-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, today announced that two studies will be presented at the 21 st Annual Meeting of Chinese Society ...

  • Reuters28 days ago

    U.S.-listed Chinese biotech Zai Lab plans Hong Kong float -sources

    HONG KONG, Aug 22 (Reuters/IFR) - Zai Lab Ltd is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said. Zai Lab is in talks with advisers for a share sale plan in Hong Kong, which is seeking to establish itself as a financing hub for pre-revenue drug developers, the sources added.

  • Reuters28 days ago

    U.S.-listed Chinese biotech Zai Lab plans Hong Kong float -sources

    HONG KONG, Aug 22 (Reuters/IFR) - Zai Lab Ltd is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said. Zai Lab is in talks with advisers for a share sale plan in Hong Kong, which is seeking to establish itself as a financing hub for pre-revenue drug developers, the sources added.

  • GlobeNewswire29 days ago

    Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced the early completion of an open-label study to evaluate the pharmacokinetic (PK) profile of ZL-2306 (niraparib) made in China in Chinese ovarian cancer patients. The study demonstrated comparable PK profile of Chinese patients who were administered ZL-2306 to the PK profile of patients evaluated in Tesaro’s clinical trials using product manufactured outside of China.

  • GlobeNewswirelast month

    Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Professor Kai-Xian Chen, Ph.D., was appointed to the Company’s Board of Directors. Prof. Chen is a globally preeminent scientist widely regarded as a pioneer in the field of interdisciplinary healthcare research. “We are honored to have Prof. Chen join our Board of Directors at this transformative time in our company,” said Dr. Samantha Du, Chief Executive Officer at Zai Lab.

  • GlobeNewswire3 months ago

    Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 3 China registration trial of ZL-2306 (niraparib) for first-line maintenance therapy of patients with platinum-responsive ovarian cancer. ZL-2306 is a highly potent and selective oral, once-daily small molecule poly (ADP-ribose) polymerase 1/2, or PARP 1/2, inhibitor with the potential to be a first-in-class Category 1 drug in China for treatment across multiple solid tumor types. In September 2017, Zai Lab commenced its Phase 3 China registration trial of ZL-2306 as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.

  • ACCESSWIRE5 months ago

    Blog Exposure - Zai Lab Inks Exclusive License Deal with Entasis for ETX2514 in the Asia/Pacific Region

    LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Zai Lab Ltd (NASDAQ: ZLAB). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZLAB as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has inked an exclusive license agreement with Entasis Therapeutics Holdings Inc. ("Entasis") for the rights to ETX2514, which is a novel broad-spectrum intravenous inhibitor of β-lactamases, in the Asia/Pacific region.

  • Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514
    Business Wire5 months ago

    Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

    Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic development collaboration. Entasis is developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii, representing a healthcare challenge of global importance with over 200,000 occurrences estimated in China each year.